Evidence shows that short-course TB preventive treatments are as effective as the current treatment of choice in preventing progression to TB disease. People taking shorter drug regimens are up to three times more likely to complete their course of TB Preventive Treatment(TPT) than those on longer regimens—leading to better outcomes and more lives saved.
Shorter TB regimens that combine two TB drugs – isoniazid and rifapentine – are now available.
Evidence shows they are as effective as the current treatment of choice in preventing progression from TB infection to TB disease. These shorter TB regimens have fewer side effects and are easier for patients to take. While they may cost more in the short term because we need fewer doses and more people complete their treatment, these shorter regimens are more cost-effective in the long term. People taking shorter drug regimens are much more likely – up to three times – to complete their course of TPT than those on longer regimens – leading to better outcomes and more lives saved.
3HP is a short-course TB preventive treatment that combines two TB drugs—isoniazid and rifapentine—once weekly for three months. The World Health Organization (WHO) recently released consolidated guidelines for the treatment of TB infection that recommend the use of 3HP for people living with HIV and contacts of TB cases of any age.
1HP is a short-course TB preventive treatment that combines two TB drugs—isoniazid and rifapentine— once daily for 28 days. The World Health Organization (WHO) recommends the use of 1HP for people living with HIV and adult contacts (>13 years) of TB cases.
